153
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients

ORCID Icon, , &
Pages 117-126 | Received 11 Dec 2023, Accepted 22 Feb 2024, Published online: 08 Mar 2024

Figures & data

Figure 1 The different expression of Ki-67 in breast cancer of tumor tissues. ((A) 5%; (B) 20%; (C) 30%; (D) 60%; SP x400).

Figure 1 The different expression of Ki-67 in breast cancer of tumor tissues. ((A) 5%; (B) 20%; (C) 30%; (D) 60%; SP x400).

Figure 2 The frequency distribution of Ki-67 value in 2015–2019.

Figure 2 The frequency distribution of Ki-67 value in 2015–2019.

Table 1 HR+/HER2- Breast Cancer at Different Cut-off Values

Table 2 Correlation of Ki-67 with Pathological for the Different Cut-off Values

Figure 3 The ROC curve of Ki-67 expression (Area under ROC curve: 0.689; Sensitivity: 63.02%; Specificity: 65.57%; Youden Index: 0.286; 95% CI: [0.626–0.754]; P <0.001;).

Figure 3 The ROC curve of Ki-67 expression (Area under ROC curve: 0.689; Sensitivity: 63.02%; Specificity: 65.57%; Youden Index: 0.286; 95% CI: [0.626–0.754]; P <0.001;).

Figure 4 The relationship between Ki-67 expression and histological grade. (Median: G1:10%; G2:20%; G3:40%. Mean: G1:13%; G2:23%; G3:39%, P <0.001).

Figure 4 The relationship between Ki-67 expression and histological grade. (Median: G1:10%; G2:20%; G3:40%. Mean: G1:13%; G2:23%; G3:39%, P <0.001).

Table 3 Univariate Analysis of Prognosis with HR+/HER2- Breast Cancer

Table 4 Multivariate Analysis of Prognosis with HR+/HER2- Breast Cancer

Figure 5 Kaplan-Meier survival curve with the expression of Ki-67.

Figure 5 Kaplan-Meier survival curve with the expression of Ki-67.

Figure 6 The common metastatic sites of HR+/HER2- breast cancer.

Figure 6 The common metastatic sites of HR+/HER2- breast cancer.